Back to top
more

Align Technology (ALGN)

(Delayed Data from NSDQ)

$256.01 USD

256.01
1,078,431

-15.27 (-5.63%)

Updated Jun 14, 2024 04:00 PM ET

After-Market: $255.40 -0.61 (-0.24%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 29% (178 out of 250)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.

Profound Medical (PROF) Adds AI to Prostate Cancer Treatment

Profound Medical's (PROF) Contouring Assistant integrates AI into prostate cancer procedures, thereby streamlining the treatment planning process and enhancing both efficiency and precision.

Reasons to Add Veeva Systems (VEEV) Stock to Your Portfolio

Veeva System's (VEEV) strong product demand and strategic deals raise optimism about the stock.

GE HealthCare (GEHC), Medis Medical Partner to Aid CAD Therapy

GE HealthCare (GEHC) and Medis Medical collaborate to boost precision care for coronary artery disease treatment.

Here's Why You Should Buy Align Technology (ALGN) Stock Now

Investors are optimistic about Align Technology (ALGN) led by expansion in new geographies and upbeat guidance.

Urmimala Biswas headshot

3 Solid Buys From MedTech Following 2024 Guidance Raise

Guidance hikes by BSX, ALGN and ALC for 2024 make them attractive investment bets.

Senseonics' (SENS) Deal With Mercy to Drive Eversense CGM Sales

Senseonics Holdings (SENS) collaborates with Mercy to bring its Eversense CGM to a healthcare system that is likely to drive its adoption.

Stereotaxis (STXS) Inks Deal to Buy Access Point Technologies

Stereotaxis' (STXS) deal to acquire electrophysiology catheter developer, Access Point Technologies, is likely to strengthen its position within the catheter market.

Philips' (PHG) Gets FDA Recall for Trilogy Ventilator Glitch

Philips' (PHG) software update for Trilogy Evo ventilators is set to mitigate a possible power malfunction and gets FDA Class I recall identification, as it may cause serious harm.

Reasons to Add The Cooper Companies (COO) to Your Portfolio

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is, however, concerning.

Reasons to Retain Intuitive Surgical (ISRG) in Your Portfolio

Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.

Orthofix Medical's (OFIX) Telescopic Nail Gets FDA Clearance

Orthofix Medical (OFIX) announces the FDA clearance of its Rodeo Telescopic Nail, which is likely to aid in curing fractures or abnormalities in individuals with osteogenesis imperfecta.

Neogen (NEOG) Faces Macroeconomic Issues, Fierce Competition

Neogen (NEOG) faces intense competition from companies ranging from small businesses to divisions of large multinational companies.

AMN Healthcare (AMN) Q1 Earnings and Revenues Beat Estimates

AMN Healthcare's (AMN) dismal results in the majority of its segments led to a soft overall first-quarter performance.

PacBio (PACB) Q1 Earnings In Line, Adjusted Gross Margin Up

PacBio (PACB) reports growth in Product revenues in the first quarter of 2024. However, Instruments revenues decline year over year due to lower shipment of Revio units.

Catalent (CTLT) Q3 Earnings Lag Estimates, Gross Margin Up

Catalent (CTLT) reports a solid revenue uptick in third-quarter fiscal 2024 despite lower revenues in Biologics segments.

Inogen (INGN) Q1 Earnings Top Estimates, Revenues Up Y/Y

Higher business-to-business sales aid Inogen's (INGN) overall first-quarter results.

QuidelOrtho (QDEL) Q1 Earnings Beat Estimates, Margins Fall

QuidelOrtho's (QDEL) first-quarter results reflect growth in revenues, excluding the COVID-19 revenue impact.

OPKO Health's (OPK) Q1 Earnings Miss Estimates, Sales Down Y/Y

OPKO Health's (OPK) first-quarter results reflect soft performances despite robust RAYALDEE sales and strength in the Pharmaceuticals segment.

McKesson (MCK) Q4 Earnings Miss Estimates, Revenues Up Y/Y

McKesson's (MCK) fourth-quarter fiscal 2024 results showcase growth in the U.S. Pharmaceutical while lower COVID-related sales hurt the Medical Surgical Solutions segment.

Nevro's (NVRO) Q1 Earnings and Sales Beat Estimates, Margins Up

Nevro's (NVRO) first-quarter earnings and revenues surpass their respective Zacks Consensus Estimate. The company incurs a loss in the operating level.

Inspire Medical (INSP) Q1 Earnings Beat, Gross Margin Up

Inspire Medical's (INSP) both geographic segments witness strong revenue growth in the first quarter.

Masimo (MASI) Q1 Earnings Beat Estimates, '24 EPS View Up

Masimo's (MASI) Q1 healthcare revenues reflect strong sensor orders, which were completely offset by lower capital equipment purchases. Sensor production in Malaysia is likely to improve Healthcare gross margin.

Fresenius Medical (FMS) Q1 Earnings Beat, Operating Margin Up

Fresenius Medical's (FMS) first-quarter revenues suffer due to unfavorable currency movement. However, the company's transformational plans continue to benefit its operating income.

Integra's (IART) Q1 Earnings Match Estimates, Margins Down

Strong demand for Integra's (IART) diverse portfolio of leading brands and continued successful market adoption of CereLink contributes to its revenues.

Quest Diagnostics (DGX) Grows in Digital Pathology With New Deal

Quest Diagnostics' (DGX) pathology laboratories nationwide are set to get a boost with PathAI's AISight digital pathology image management system.